Last edition
News about "cancer cell death"
SystImmune and BMS Present Phase I Results of EGFR x HER3 Bispecific ADC at ESMO 2025
Iza-bren, a potentially first-in-class EGFR x HER3 bispecific Antibody-Drug Conjugate (ADC), is jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive licence agreement in territories outside of Mainland China.
Cancer Cell Death | 21/10/2025 | By Dineshwori | 139
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members